NCT06804850 2025-11-19
Neoadjuvant Radiotherapy Plus Targeted Therapy and Immunotherapy vs. Targeted Therapy Plus Immunotherapy in Resectable HNSCC
West China Hospital
Phase 2 Withdrawn
Clinical Trials
5 trialsNCT05690035 2024-07-09
Tislelizumab Combined With Fruquintinib for Metastatic pMMR/MSS Colorectal Cancer
Sun Yat-sen University
Phase 2 Withdrawn
NCT05809895 2023-07-24
AdvanTIG-211
Novartis
Phase 2 Withdrawn
NCT05614453 2023-06-29
ITTACC
Australia New Zealand Gynaecological Oncology Group
Phase 2 Withdrawn
NCT05582031 2023-06-07
REFIT-MSS
Translational Research in Oncology
Phase 2 Withdrawn